Key Highlights
- Revenue was a record USD 12.3 million, up 22%.
- Gross Margin was 71.3%, compared with 63.8%.
- Record orders of 258 MyoPro units, up 13%.
- Adjusted EBITDA was breakeven, compared with a USD 2.7 million loss.
Myomo Inc. (NYSEAMERICAN:MYO) reported third quarter 2026 Revenue of a record USD 12.3 million, up 22% from a year ago. Reported EPS was negative USD 0.10 and revenue was USD 12.33 million, compared with estimates of EPS of negative USD 0.08 and revenue of USD 11.51 million.
Chief Executive Officer Paul R. Gudonis said the results reflect execution on four success pillars: building recurring patient sources, expanding payer access, demonstrating Operating Leverage and investing in product development and clinical research.
Revenue and Orders
The company recognized revenue on a record 222 MyoPro units, an increase of 19% over the third quarter of 2025, at an average selling price of approximately USD 55.5 thousand, up about 2%. Orders reached a record 258, up 13% year over year. The company added 600 patients to the pipeline, down compared with the second quarter, and ended the quarter with a Backlog of 217 patients, down modestly from the second quarter.
Management said direct to patient Advertising spending was up 2% year over year and that an inefficiency in lead generation resulted in fewer workable leads and a lower conversion rate in the quarter. It said direct billing pipeline additions in October were approximately 30% above the third quarter monthly average.
Recurring Patient Sources and Payers
Recurring patient sources, including referrals from rehab hospitals and stroke clinics, orthotics and prosthetics partners and the VA, represented 54% of third quarter revenue, compared with 33% a year ago. Direct billing referrals through the MyoConnect program generated 27% of total revenue, up from 23% in the second quarter and 20% in the first quarter of 2026. International revenue was 17% of revenue, orthotics and prosthetics revenue was 8% and VA patients were 2%.
Healthcare professionals at more than 500 rehabilitation facilities and therapy centers have referred potential patients, an increase of over 200 locations in the past quarter. Medicare Part B patients represented 54% of both third quarter revenue and prior year period revenue, and Medicare Advantage plans represented 17% of revenue. During the quarter the company entered into or was finalizing agreements with payers covering an additional 35 million lives and was enrolled with seven state Medicaid agencies.
Costs and Profitability
Gross margin was 71.3%, up from 63.8% in the prior year quarter. Operating expenses were USD 10.5 million, an increase of 6% compared with the third quarter of 2025. Operating loss improved to USD 1.7 million from USD 3.5 million. Adjusted EBITDA was breakeven, compared with a loss of USD 2.7 million a year ago.
Results included a non-cash charge of approximately USD 1.8 million related to the valuation of derivative liabilities, as well as interest expense associated with the Avenue Capital term loan. Net loss was USD 4.2 million, or USD 0.10 per share, compared with USD 3.7 million, or USD 0.09 per share, in the third quarter of 2025.
Cash, cash equivalents and short term investments were USD 11.9 million as of September 30, 2026. Cash used in Operating Activities was USD 1.3 million, compared with USD 1.8 million a year earlier, and cash burn in the quarter was USD 1.5 million, compared with USD 2.2 million in the second quarter.
The randomized control trial at the University of Utah has enrolled 35 of the planned 50 subjects, up from 25 at the time of the second quarter call. Development work continued on MyoPro 3 and on a hand only product for the German market.
Recurring Sources, Payers and Cash
Myomo's record revenue of USD 12.3 million came with 258 orders, 222 units recognized and recurring patient sources at 54% of revenue. Management cited the payer mix, the MyoConnect share of revenue and USD 11.9 million of cash, cash equivalents and short term investments.






Please wait processing your request...